Skip to main content

Table 1 Baseline demographic data and cumulative clinical and serological data of the study cohort

From: Ultrasonographic assessment of bone erosions in the different subtypes of systemic lupus erythematosus arthritis: comparison with computed tomography

  SLE (n = 26) Rhupus syndrome (n = 9) Jaccoud’s arthropathy (n = 10) NDNE (n = 7)
Age (mean ± SD) 49.4 ± 16.0 41.1 ± 5.7 61.3 ± 14.3 43.1 ± 16.5
Disease duration (mean ± SD) 15.6 ± 8.2 13.7 ± 6.7 21.7 ± 8.5 10.8 ± 4.5
Gender, female, n 26 9 10 7
Cumulative 1997 ACR criteria
 Malar rash 12 (46.2) 5 (55.5) 4 (40.0) 3 (42.8)
 Discoid rash 2 (7.7) 0 1 (10.0) 1 (14.3)
 Photosensitivity 4 (15.4) 1 (11.1) 2 (20.0) 1 (14.3)
 Oral/nasopharyngeal ulcers 2 (7.7) 0 1 (10.0) 1 (14.3)
 Serositis 15 (57.7) 4 (44.4) 8 (80.0) 3 (42.8)
 Renal disorders 5 (19.2) 0 2 (20.0) 3 (42.8)
 Neurologic disorders 2 (7.7) 0 2 (20.0) 0
 Hematological disorders 14 (53.8) 5 (55.5) 7 (70.0) 2 (28.6)
 ANA 26 (100) 9 (100) 10 (100) 7 (100)
 Anti-dsDNA 18 (69.2) 6 (66.7) 8 (80.0) 4 (57.1)
 Antiphospholipid antibodies 7 (26.9) 3 (33.3) 3 (30.0) 1 (14.3)
Other laboratory findings
 Anti-Ro/SSA 14 (53.8) 4 (44.4) 5 (50.0) 5 (71.4)
 Anti-La/SSB 2 (7.7) 0 1 (10.0) 1 (14.3)
 Anti-RNP 2 (7.7) 0 0 2 (28.6)
 Anti-Sm 2 (7.7) 0 0 2 (28.6)
 Rheumatoid factor 11 (37.9) 7 (77.8) 1 (10.0) 3 (42.8)
 Anti-CCP 7 (26.9) 6 (66.7) 0 1 (14.3)
SLICC/damage index (mean ± SD) 1.4 ± 1.3 1.4 ± 0.5 2.6 ± 1.3 0.6 ± 0.5
Medication receiveda
Total corticosteroid dose >50 g 15 (57.7) 3 (33.3) 10 (100) 2 (28.6)
Antimalarial agents 25 (96.1) 8 (88.9) 10 (100) 7 (100)
Methotrexate 20 (76.9) 9 (100) 6 (60.0) 5 (71.4)
Azathioptine 7 (26.9) 1 (11.1) 4 (40.0) 2 (28.6)
Micophenolate 4 (15.4) 1 (11.1) 1 (10.0) 2 (28.6)
Rituximab 8 (30.7) 4 (44.4) 2 (20.0) 2 (28.6)
Belimumab 1 (3.8) 0 0 1 (14.3)
Anti TNF-alpha 3 (11.5) 3(33.3) 0 0
Anti IL-6 2 (7.7) 1 (11.1) 1 (10.0) 0
  1. Unless otherwise specified, values are the number of patients (values in brackets are percentage). aIncludes medication ongoing at enrollment and past treatment. Antiphospholipid antibodies included lupus anticoagulant, anticardiolipin antibodies IgG and IgM, beta2-glicoproteinI IgG and IgM. Anti-extractable nuclear antigens (SSA, SSB, Sm, RNP, Rheumatoid factor and anti-cyclic citrullinated peptide antibodies (antiCCP) were tested by ELISA. Antinuclear antibodies (ANA) were tested by IIF, using Hep2 cell substrate; positivity was defined as a titer ≥1:320. Anti-double-stranded DNA (Anti-dsDNA) antibodies were tested by Farr assay. SLE systemic lupus erythematosus, NDNE non-deforming non-erosive, ACR American College of Rheumatology, SLICC Systemic Lupus International Collaboration Clinics